RT Journal Article
T1 PTGDR2 Expression in Peripheral Blood as a Potential Biomarker in Adult Patients with Asthma.
A1 Garcia-Sanchez, Asuncion
A1 Estravis, Miguel
A1 Martin, Maria J
A1 Perez-Pazos, Jacqueline
A1 Martin-Garcia, Cristina
A1 Gil-Melcon, Maria
A1 Ramos-Gonzalez, Jacinto
A1 Eguiluz-Gracia, Ibon
A1 Triviño, Juan Carlos
A1 Isidoro-Garcia, Maria
A1 Davila, Ignacio
A1 Sanz, Catalina
K1 PTGDR2
K1 Aspirin exacerbated respiratory disease (AERD)
K1 Asthma
K1 Biomarker
K1 Chronic rhinosinusitis with nasal polyps (CRSwNP)
K1 Gene expression
AB Precision medicine is a promising strategy to identify biomarkers, stratify asthmatic patients according to different endotypes, and match them with the appropriate therapy. This proof-of-concept study aimed to investigate whether gene expression in peripheral blood could provide a valuable noninvasive approach for the molecular phenotyping of asthma. We performed whole-transcriptome RNA sequencing on peripheral blood of 30 non-atopic non-asthmatic controls and 30 asthmatic patients. A quantitative PCR (qPCR) validation study of PTGDR2 that encodes for CRTH2 receptor, expressed in cells involved in T2 inflammation, was developed in a cohort of 361 independent subjects: 94 non-asthmatic non-atopic controls, 187 asthmatic patients [including 82 with chronic rhinosinusitis with nasal polyposis (CRSwNP) and 24 with aspirin-exacerbated respiratory disease (AERD)], 52 with allergic rhinitis, and 28 with CRSwNP without asthma. PTGDR2 was one of the most differentially overexpressed genes in asthmatic patients' peripheral blood (p-value 2.64 × 106). These results were confirmed by qPCR in the validation study, where PTGDR2 transcripts were significantly upregulated in asthmatic patients (p  We found that PTGDR2 expression levels could identify asthma patients, introduce a minimally invasive biomarker for adult asthma molecular phenotyping, and add additional information to blood eosinophils. Although further studies are required, analyzing PTGDR2 expression levels in peripheral blood of asthmatics might assist in selecting patients for treatment with specific antagonists.
SN 2075-4426
YR 2021
FD 2021-08-24
LK http://hdl.handle.net/10668/18577
UL http://hdl.handle.net/10668/18577
LA en
NO This research was funded by the Instituto de Salud Carlos III and the European Regional Development Fund, grants numbers PI17/00818 and PI20/00268 and a Juan Rodes contract for IEG (JR19/00029), a grant from Junta de Castilla y León co-financed by the European RegionalDevelopment Fund (IES161P20) and a grant from the Gerencia Regional de Salud de la Junta de Castilla y León (GRS2156/A/20), a 2019 grant of the Sociedad Española de Alergia e Inmunología Clínica (SEAIC), the Consejería de Educación-Plan operativo de Empleo Juvenil de Castilla y Leónand the European Social Fund and Youth Employment Initiative and the Instituto de Salud Carlos III’s Thematic Network of Cooperative Research in Health—RETICS (Red temática de investigación en salud Asma, Reacciones Adversas y Alérgicas, ARADYAL), grant number RD16/0006/0019 and RD16/0006/0001.
DS RISalud
RD Apr 5, 2025